Cyclopharm’s Technegas radiopharmaceutical imaging system has achieved a streamlined reimbursement approval process in the United States, boosting its prospects in what is the world’s largest market. The Sydney company has received a Coding Determination for Technegas from the Center for Medicare Medicaid Services (CMS), which means users will have a unique identifier which streamlines their…
DroneShield moves to profit on increasing global tensions Drone countermeasure company DroneShield has confirmed it moved to profit in FY23 on the back of rising global tensions and Russia’s invasion of Ukraine. The company reported record contracts and growing cash receipts which reached $73.5 million in FY23, five times the previous year. More than 68…
Radiopharmaceutical manufacturer Cyclopharm has announced unaudited FY23 revenue up 14 percent to $28.9 million and increasing momentum in the roll out of its Technegas lung imaging technology in the United States. The US launch has resulted in 80 issued contracts to date, covering more than 280 individual institutions, of which six are at the final…
Viraleze shows efficacy in Covid-19 patients – Starpharma Starpharma’s Viraleze antiviral nasal spray has demonstrated antiviral efficacy in a placebo-controlled study in participants with Covid-19. Viraleze achieved a statistically significant reduction in SARS-CoV-2 viral load, in the cohort of participants aged 45 and over. Viral load in the nose was reduced by 80 percent less…
Radiopharmaceutical manufacturer Cyclopharm has announced that Duke University Hospital in the United States has signed the first commercial contract for the use of its Technegas lung imaging system in the United States. Following the approval of Technegas by the United States Food and Drug Administration (USFDA) in September, this agreement signifies a major milestone for…
Radiopharmaceutical systems manufacturer Cyclopharm is expanding its manufacturing and storage capacity at Kingsgrove in Sydney to meet US demand, following approval by the USFDA for sale of the system in the big Uited States market. The Sydney company told investors it was preparing to air freight the first 20 Technegas systems to the USA, with…
The US Food and Drug Administration has approved Cyclopharm’s lung imagining technology Technegas, opening up a US$180 million market that has the potential to quadruple the size of Cyclopharm’s existing Pulmonary Embolism (PE) market. Technegas is an ultra-fine dispersion of the radiopharmaceutical Technetium-99m within a gas used in diagnostic functional lung imaging in 64 countries…
Radiopharmaceutical producer Cyclopharm has announced record sales revenue for 1H FY23 of $15.3 million, up 39 percent on the previous corresponding period. Sales of its Technegas product were steady on the previous corresponding period, with third party distribution sales up 116 percent on the PCP to $7.7 million. For the first time third party sales…
